Replies to post #382098 on Innovation Pharmaceuticals Inc (IPIX)

[Hugon]

Here’s to no deaths!

[stocksbelow1]

Maybe I'm mistaken, but the premise behind running a clinical trial is to determine if a drug works or doesn't work, and to what degree in either direction based on statistical analysis of the trial data.

"If the brilacidin study has eight fewer deaths than the comparison arm, I think IPIX supporters would sing a different tune, especially if tere were no deaths at all in the brilacidin arm.

But I can guarantee you it won't. It's simply not powered enough."

It seems you can already guarantee the results of the Clinical Trial before the results?

Interesting!

GLTA!

$IPIX$

[farrell90]

It is not false and the study report confirms the statement.

"Statistically, most will be fine and recover on their own without Molunpriavir or much help from hospitals."



Recent reports of the phase 3 interim report show 7.4% in the molunpiravir were hospitlized with zero deaths

The placebo group had 14.1 hospitalized including 8 deaths.

The results do show a very positive treatment effect,

but 85.9% of the placebo group survived without hospitalization.

https://www.pharmaceutical-technology.com/news/merck-ridgebacks-molnupiravir-covid-19/

[thefamilyman]

I recall reading about a study a few years ago where the BP used a substance in the placebo that would produce the same adverse events that they were expecting their drug to produce. That way their new drug did not look as bad because the placebo caused just as many SAEs as the drug. I do not think the FDA properly exercises oversight when it comes to BPs; so I do not trust Merck, particularly under these circumstances. The EUA will protect them from significant liability and then proving that molnupiravir caused your cancer is a very steep uphill climb anyway. It’s a perfect opportunity for an unethical company to make big money at our expense. Because of the limit on liability, the actuaries can easily predict that the costs incurred for even a significant number of deaths is worth the risk. No, I do not trust Merck.

Merck said,

…no deaths were reported in patients who received molnupiravir, as compared to 8 deaths in patients who received placebo